The Role of 18F-PSMA PET in Prostate Cancer Diagnosis in Equivocal MRI

This study is a multi-center RCT to compare the clinically significant prostate cancer (csPCa) detection and/or change in clinical management in MRI guided (MRI arm) biopsy and MRI+18F-PSMA guided (Combined arm) biopsies in men with equivocal MRI prostate scans. If additional clinical value is shown by adding 18F-PSMA PET to equivocal MRI, then this should be the new standard of care.

NCT Number	NCT07386496
Lead Sponsor	Chinese University of Hong Kong
Conditions	Prostate Cancer
Enrollment	250 participants
Start Date	2026-03-01
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-02-04